Glenmark Pharmaceuticals has agreed to a $29.6 million settlement in response to allegations of inflated prices for certain generic drugs in the U.S. market. The settlement concludes a pricing lawsuit against their US division.

Glenmark USA has agreed to a $29.6 million settlement spread over five years, resolving antitrust lawsuits regarding price fixing that have been ongoing since 2016. Despite this settlement, the company's overall financial position remains unchanged.

Ajit Mishra of Religare Broking suggests investing in Glenmark Pharma, Manappuram Finance, and Angel One for quick profits due to uncertain global conditions. He advises a careful approach by focusing on individual stocks and managing risks accordingly.

Glenmark's biotech division, IGI, is making strides in cancer therapy, developing ISB 2301 - a treatment that targets solid tumors such as lung and breast cancer. This innovative therapy, employing BEAT technology, stimulates T and NK cells. Clinical trials for ISB 2301 are expected to commence in 2027, following an IND submission in 2026.

Glenmark Pharmaceuticals is set to review their financial results and determine a potential dividend during a board meeting on May 29, 2026. Shares of the company are currently under restrictions due to the SEBI insider trading regulations, with the trading window closed from March 31 until May 31.

Bandhan Bank could see an uptrend with a suggested buy point of over Rs 185, aiming for potential gains up to Rs 205. SBI Life Insurance is predicted to reach Rs 1,970, with support at Rs 1,850. Hexaware, Angel One, Arvind, and Glenmark exhibit bullish signals. On the contrary, Lodha Developers may face selling pressure, with a possible target of Rs 835.

ICICI Securities advises investors to consider buying IEX and Glenmark Pharma in the short term, as they show potential due to shifting market trends and support/resistance levels. However, Titan is recommended for a sell strategy, given its current position within these patterns.

Glenmark Pharmaceuticals has entered the U.S. market with a new product - Vancomycin Hydrochloride injection in both 500mg and 1g vials. This drug, similar to Fresenius Kabi's, targets a potential annual market of $37.9 million.

Based on the latest analysis by MarketsMojo, dated May 12, 2026, Glenmark Pharmaceuticals receives a "Strong Buy" rating. This positive assessment reflects Glenmark's current robust financial standing as of the same date.

New optimistic investments have been made in companies such as Cochin Shipyard, Siemens, Glenmark, Mazdock, and Crompton, indicating a growing bullish sentiment in diverse market sectors, according to NSE data. The increasing prices with higher open interest suggest these stocks may experience further growth.

Glenmark Pharma reached a record high of Rs 2,364 on April 28, 2026, reflecting the company's robust expansion and prominent standing within the pharmaceutical industry.

Axis Sec's Rajesh Palviya suggests investing in Glenmark Pharma, Marico, and SAIL during market downturn, while Infosys and the IT sector have a 3% decline, with Nifty 50 and Sensex experiencing a third consecutive session of drops.

Investment advisor Ajit Mishra from Religare Broking recommends buying Glenmark, JSW Energy, and Marico for short-term gains due to market fluctuations. He predicts Glenmark could reach ₹2,530, JSW Energy ₹605, and Marico ₹835. Each stock also comes with suggested stop-loss levels for risk management.

The Nifty index surged 1.63% to reach 24,231.3, with sectors like IT, realty, and energy driving the growth. Notably, midcaps outperformed in this session. Additionally, stocks like SBI, Glenmark Pharma, and Tata Power demonstrated bullish trends, prompting buy recommendations from analysts.

Glenmark Pharmaceuticals has received FDA approval for their Progesterone Vaginal Inserts, making them equivalent to Endometrin. This new product could potentially tap into the US market worth $59.2 million by February 2026.

The potential US implementation of a 100% tariff on imported pharmaceuticals could pose a significant disruption for Indian contract development and manufacturing organizations (CDMOs) such as Piramal Pharma, Glenmark, and Sun Pharma. This could lead to market uncertainties for these key players in the pharma industry.

The US tariff threat on certain medicines has caused Indian pharma stocks to decline, with notable drops seen in Biocon, Sun Pharma, Glenmark, Aurobindo, and Ipca Labs by 4-5%. The Nifty Pharma index fell by 3.8% due to these concerns about reshoring production.

Despite the overall bearish trend in April, the pharmaceutical sector stands out, with stocks like Astral, Aurobindo Pharma, Sun Pharma, Glenmark, NALCO, and Oil India performing well. Conversely, ICICI Prudential Life and BEL exhibit negative trends, suggesting potential challenges ahead. Investors should keep a close eye on the critical support at 21,700 for the Nifty index.

Glenmark has entered the weight loss market with Glipiq (semaglutide), priced affordably at ₹1,300-1,800/month. This move aims to increase accessibility and volumes. The company's Q3 revenue rose by 15% YoY, reaching ₹3,901 crore, primarily due to growth in specialty products, global brand expansion, and complex generics, which also boosted the Ebitda margin to 22%.

Glenmark Pharmaceuticals plans to commercialize its first US product, Ryaltris, directly starting April 2026. Currently approved and available in 55 countries, this marks an expansion of the drug's availability into the American market.

Glenmark Pharma has been issued a GST demand for approximately INR 16.1 crores from FY 2019-21. The company, however, expects no significant financial or operational impact and plans to appeal the decision.